Sequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/in Clinical Trial, Phase 1/by MaxOP-3136: New Drug Receives FDA Clearance to Begin Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dawn for Disease Treatment: Combining mRNA and RNAi Therapies
/in CRISPR, Preclinical Research/by MaxNewsletter 4
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the fourth newsletter from the site. In the next days I will be reporting some (hopefully) good news from an immune oncology symposium, fingers crossed! Some of the subscribers suggested me to reactivate the donations button, do you […]
Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/in Not PCa related, Preclinical Research/by MaxPreclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC March 20, 2026
- AUTOTAC Degraders ATB‑238 and ATB‑239 Target AR and AR‑v7 in Advanced Prostate Cancer March 20, 2026
- ²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer March 20, 2026
- HLX3902: A Trispecific T‑Cell Engager Rewiring the Immune Desert in Prostate Cancer March 19, 2026